High Throughput Screening Market Research Report - Forecast till 2030

High Throughput Screening Market Research Report: Information by Product & Service (Reagents & Assay Kits, Instruments, Consumables & Accessories, Software, and Services), Technology {Cell-Based Assays, 2D Cell Culture, 3D Cell Culture [Scaffold-Based Technologies (Hydrogels, Inert Matrix, and Micropatterned Surfaces) Scaffold-free Technologies (Microplate, Hanging-drop Plates, Ultra-low Binding Plates, and Other Scaffold-free Technologies)], Perfusion Cell Culture, Lab-on-a-Chip (LOC), Ultra-High-Throughput Screening, Bioinformatics, Label

ID: MRFR/LS/0772-HCR | December 2022 | Region: Global | 115 Pages         

High Throughput Screening Market

The high throughput screening market was worth USD 17,142.07 Million in 2030 and is expected to grow at a CAGR of 11.40% during the forecast period 2022 to 2030.

Segmentation

By Product &amp Service Reagents & Assay Kits Instruments Consumables & Accessories Software and Services
By Technology Cell-Based Assays 2D Cell Culture 3D Cell Culture [Scaffold-Based Technologies (Hydrogels Inert Matrix Micropatterned Surfaces) Scaffold-free Technologies (Microplate Hanging-drop Plates Ultra-low Binding Plates Other Scaffold-free Technologies

Key Players

  • Aurora Biomed Inc (Canada)
  • Danaher (US)
  • PerkinElmer (US)
  • Tecan (Switzerland)
  • Hamilton (US)
  • Axxam (Italy)
  • Merck Group (Germany)
  • Corning (US)
  • BioTek (US)
  • Beckman Coulter Inc. (US)

Drivers

  • The growth in this market is high throughput screening market has gotten much more technologically advanced and sophisticated
Speak to Analyst Request a Free Sample

High Throughput Screening Market Overview:


The High Throughput Screening Market is projected to reach USD 17,142.07 Million by 2030 at 11.40% CAGR during the forecast period 2022-2030. High throughput screening is a method used to find and create new medications. The method entails many processes, including target identification, reagent preparation, compound management, assay creation, and high-throughput library screening, in which a significant number of biological effectors and modulators are screened against the targeted substance. High-throughput screening methods are also helpful in lowering the price of medication development. Additionally, this method aids in screening numerous compounds via high-throughput screening, which can screen up to at least 10,000 compounds each day, and ultrahigh-throughput screening, which may screen up to 100,000 tests.


The procedure is controlled by software, robotics, and a detector in this method. Additionally, it is used to screen various libraries, including those for combinatorial chemistry, peptides, genomics, and proteins. It is also used to describe the toxicological, pharmacokinetic, and metabolic information regarding novel medications due to factors including the increased usage of high-throughput screening for drug development, which shortens the time needed to produce medicine. Creating novel medications for various disorders that pose a severe threat to life also helps the market expand.


According to technology, label-free technology is anticipated to experience faster growth during the forecast period because it offers straightforward approaches for understanding intricate biological pathways and lowers the likelihood that toxic drugs will fail, both of which support the development of the high throughput screening market.


COVID-19 analysis


COVID-19 impacted the world beginning in March of last year. It did a lot of damage around the world and overwhelmed many nations’ healthcare systems. These two factors made governments around the world realize that it was a dangerous virus that must be controlled. These governments imposed lockdowns and quarantines. These had a limited effect so they were temporary.


Many industries and markets were negatively affected. The high throughput screening market was one of these. Because many of the companies in the industries that companies in the market relied upon for raw materials either stopped operations or scaled back production, it became harder to make these processes available for researchers. The manufacturers also found that their production costs went up. They were forced to raise the final retail price to recoup these losses.


Market dynamics


Drivers


One main driver of growth in this market is the fact that the high throughput screening market has gotten much more technologically advanced and sophisticated in recent years. Pharma majors are also spending much more in terms of research and development, although, admittedly, a good chunk of it went and still goes to finding effective vaccines for the different strains of COVID-19.


The government and private venture capitalists are also pouring millions in terms of research and development to find better high throughput screening processes. Finding a long-term effective vaccine for COVID-19 has been a main motivating factor for this.


Opportunities


Many companies in the high throughput screening market are seeing that this market is potentially very lucrative. That’s why they are pouring billions into research and development. The goal is to find processes that are cost-effective and much more effective/efficient than the previous processes were. They also want to find processes that work on the first try and with as little assistance from aides and devices as possible.


Restraints


There is a factor that is holding back growth in this market. It is the fact that it is expensive to consistently find newer and better high throughput screening market processes. The fact that the capital to fund these efforts is hard to come by, especially during the pandemic, only compounds this.


Challenges


Companies in the high throughput screening market face a huge challenge. This lies in finding ways to lower the costs of finding newer processes. This will help pharma majors lower the price of the pharma blockbuster drugs that they sell. Many customers have found that these prices have been rising at alarmingly high levels in recent years.


Cumulative growth analysis


The high throughput screening market will register a CAGR of 7.5% until 2025. The market was worth USD 13,460 million in 2018.


Technology analysis


Aurora Biomed Inc is a major Canadian player in the high throughput screening market. It has managed to retain its superior position by investing heavily in research and development. This allowed it to create a sustainable competitive advantage by consistently developing and marketing newer and improved market processes. Incidentally, this also allowed it to justify charging more for these processes.


Segment overview


By product and service


The high throughput screening market can be divided into the following sub-segments based on product and service:



  • Reagent and assays kits

  • Instruments

  • Consumables and accessories

  • Software

  • Services


The reagent and assays kits subsegment currently hold the largest high screening throughput market share. The reason for this is because the high screening throughput market uses many reagent and assays kits as part of the process of finding newer and more effective drugs. The federal government is noticing. It is allocating more funds to research in the life sciences area.


By technology


The high throughput screening market can be divided into the following sub-segments based on technology:



  • Cell-based assays

  • 2D cell culture

  • 3D cell culture

  • Perfusion cell culture

  • Lab-on-a-chip

  • Ultra-high throughput screening

  • Bioinformatics

  • Label-free technology


The 3D cell culture sub-segment can be divided further into these groups:



  • Scaffold-based technologies

  • Scaffold-free technologies


The scaffold-based group can be further segregated into:



  • Hydrogels

  • Inert matrix

  • Micropatterned surfaces


The scaffold-free group can be further segregated into:



  • Microplate

  • Hanging drop plates

  • Ultra-low binding plates

  • Other technologies that don’t have scaffolds.


By application


The high throughput screening market can be divided into the following sub-segments based on application:



  • Target identification and validation

  • Primary and secondary screening

  • Toxicology assessment

  • Others


The application segment has the greatest market growth. This is attributed to the fact that there are more diseases popping up and the fact that more entities are investing more in research and development.


By end-user


The high throughput screening market can be divided into the following sub-segments based on end-user:



  • Pharma and biotech companies

  • Academic institutes and government agencies

  • Contract research organizations

  • Others


By region


The high throughput screening market can be divided into the following sub-segments based on region:



  • North America

  • South America

  • The European Union

  • Asia-Pacific

  • The Middle East and Africa


Regional analysis


The Americas market is further separated into North and South America. The North American market has been further divided into the nations of The United States of America, Canada.


The European Union market has been further separated into Western Europe and Eastern Europe. Western Europe can be divided into the following regions: Germany, France, Spain, the United Kingdom, Italy, and the rest of Europe.


The Asia-Pacific market can be further separated into Japan, China, India, Australia, South Korea, and the rest of the Asia-Pacific market.


The Middle East and Africa have been divided into the Middle East and African regions.


The Americas will have the greatest high throughput screening market share because the government and private companies are spending much more on healthcare. The pharma and healthcare companies are also spending much more on technologies that are designed to improve the overall quality of healthcare.


Canada, especially, is using HTS more and more often in its drug discovery processes. The pharma and healthcare companies throughout North America are also spending much more on research and development.


The European Union will have the greatest high throughput screening market growth. This is largely attributed to the fact that many European countries have a good healthcare system. There are also many European healthcare companies located throughout the European Union. The EU government allocated 7% of its overall gross domestic product to spending on healthcare in 2017.


The Asia-Pacific region will see respectable growth. This is largely attributed to greater governmental spending in healthcare and the growing prevalence of dangerous diseases there.


Competitive landscape


The high throughput screening market is very competitive despite there being high barriers to entry. The fact that there are formidable players in the market makes companies resort to one or more of three measures to survive and stay profitable:



  • Investing in research and development

  • Merging with/acquiring other companies

  • Entering into strategic partnerships with other companies.


Aurora Biomed Inc is a major Canadian player. It has succeeded by investing heavily in research and development. This has allowed it to develop a new generation of highly successful and effective high throughput screening processes.


List of companies



  • Aurora Biomed Inc. (Canada),

  • Danaher (US),

  • PerkinElmer (US),

  • Tecan (Switzerland),

  • Hamilton (US),

  • Axxam (Italy),

  • Merck Group (Germany),

  • Corning (US),

  • BioTek (US),

  • Beckman Coulter, Inc. (US),

  • Agilent Technologies Inc. (US),

  • Luminex Corporation (US), and

  • Roche (Switzerland).


Recent Developments


Each experiment generates more data as throughput rises, and scientists use this data to evaluate patterns and draw conclusions. The necessity for considerable automation solutions to simplify the processes emerges from the massive volume of samples being processed and the enormous amount of data generated.



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 17,142.07 Million
  CAGR   11.405
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Product & Service, Technology, Applications and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Aurora Biomed Inc. (Canada), Danaher (US), PerkinElmer (US), Tecan (Switzerland), Hamilton (US), Axxam (Italy), Merck Group (Germany), Corning (US), BioTek (US), Beckman Coulter, Inc. (US), Agilent Technologies Inc. (US), Luminex Corporation (US), and Roche (Switzerland).
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Technological advancements in HTS.
  • Increased budget of the pharmaceutical industry coupled with advances in high throughput screening


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    High Throughput Screening Market is expected to inflate at a CAGR of 11.40% from 2022-2030.

    High Throughput Screening Market valuation stood at USD 17,142.07 Million in 2030.

    Increased budget of the pharmaceutical industry coupled with advances in high throughput screening can drive the High Throughput Screening Market.

    Americas are purported to dominate the High Throughput Screening Market.

    Luminex Corporation, Corning, Aurora Biomed Inc., PerkinElmer, BioTek, Tecan, Roche, Merck Group, Axxam, Beckman Coulter, Inc., Danaher, Agilent Technologies Inc., and Hamilton are major players of the High Throughput Screening Market.